Comparative Pharmacology
Head-to-head clinical analysis: METHADOSE versus OXYCODONE 5 APAP 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHADOSE versus OXYCODONE 5 APAP 500.
METHADOSE vs OXYCODONE 5/APAP 500
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Oxycodone: mu-opioid receptor agonist; Acetaminophen: cyclooxygenase (COX) inhibition, analgesic and antipyretic via central action.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
1-2 tablets (oxycodone 5-10 mg/APAP 500-1000 mg) orally every 4-6 hours as needed for pain; maximum APAP dose 4000 mg/day from all sources.
None Documented
None Documented
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Oxycodone: Terminal half-life 3.5-5.6 hours (mean 4.5 h); prolonged in renal/hepatic impairment. Acetaminophen: 2-3 hours.
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Renal: Oxycodone ~87% (10% unchanged, 77% as metabolites); Acetaminophen ~85% (2-5% unchanged, rest as glucuronide and sulfate conjugates). Biliary/fecal: Minimal for both.
Category C
Category D/X
Opioid Agonist
Opioid Agonist